期刊
JOURNAL OF LIPID RESEARCH
卷 49, 期 4, 页码 763-772出版社
ELSEVIER
DOI: 10.1194/jlr.M700293-JLR200
关键词
nuclear receptor; intestine; leukemia; calcium
1 alpha,25-Dihydroxyvitamin D-3 [1,25(OH)(2)D-3], a vitamin D receptor (VDR) ligand, regulates calcium homeostasis and also exhibits noncalcemic actions on immunity and cell differentiation. In addition to disorders of bone and calcium metabolism, VDR ligands are potential therapeutic agents in the treatment of immune disorders, microbial infections, and malignancies. Hypercalcemia, the major adverse effect of vitamin D-3 derivatives; limits their clinical application. The secondary bile acid lithocholic acid (LCA) is an additional physiological ligand for VDR, and its synthetic derivative, LCA acetate, is a potent VDR agonist. In this study, we found that an additional derivative, LCA propionate, is a more selective VDR activator than LCA acetate. LCA acetate and LCA propionate induced the expression of the calcium channel transient receptor potential vanilloid type 6 (TRPV6) as effectively as that of 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase (CYP24A1), whereas 1,25(OH)(2)D-3 was more effective on TRPV6 than on CYP24A1 in intestinal cells. In vivo experiments showed that LCA acetate and LCA propionate effectively induced tissue VDR activation without causing hypercalcemia. These bile acid derivatives have the ability to function as selective VDR modulators.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据